Shanghai Duyiwei Biotechnology

Shanghai Duyiwei Biotechnology is a Chinese biopharmaceutical company specializing in the development of monoclonal antibody therapeutics. Established as a research and development arm of Hengkang Medical Group (now New Journey Health Group), the company focuses on creating both biosimilars and innovative biologics for oncology indications. Its pipeline includes candidates targeting well-validated pathways such as PD-1, HER2, and VEGF. The company operates out of Shanghai's high-tech industrial zones, utilizing mammalian cell expression platforms for protein production. While it made significant strides in early-stage clinical filings, its progress has been closely tied to the strategic shifts of its parent corporation. The company aims to provide high-quality, affordable biologic treatments to the Chinese market.